display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HR positive
la/mBC - HR-positive - 2nd line (L2)
alisertib plus paclitaxel NCT02187991 - HR-positive and HER2-negative cohort

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons